All In Biotech

Drug Trial Radar · NCT00239681

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein

Last checked: Nov 20, 2026Latest source record: Mar 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 17,802 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

17,802

Actual

Start

Feb 2003

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 17, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.

Conditions

  • Elevated High-sensitivity C-Reactive Protein (hsCRP)

Interventions

  • RosuvastatinDrug

    Oral

  • PlaceboOther

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Major Cardiac Event (Cardiovascular Death, Stroke, Myocardial Infarction, Hospitalization Due to Unstable Angina or Arterial Revascularization)Time frame: up to 5 years

Locations

856 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Calera, Alabama

  • Research Site

    Columbiana, Alabama

  • Research Site

    Decatur, Alabama

  • Research Site

    Graysville, Alabama

  • Research Site

    Haleyville, Alabama

  • Research Site

    Hartselle, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Montgomery, Alabama

  • Research Site

    Muscle Shoals, Alabama

  • Research Site

    South Birmingham, Alabama

  • Research Site

    Tuscumbia, Alabama

  • Research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Fayetteville, Arkansas

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Pine Bluff, Arkansas

  • Research Site

    Alhambra, California

  • Research Site

    Azusa, California

  • Research Site

    Berkeley, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Burlingame, California

  • Research Site

    Carmichael, California

  • Research Site

    Concord, California

  • Research Site

    Culver City, California

  • Research Site

    Daly City, California

  • Research Site

    Folsom, California

  • Research Site

    Foothill Ranch, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Fresno, California

  • Research Site

    Garden Grove, California

  • Research Site

    Inglewood, California

  • Research Site

    Irvine, California

  • Research Site

    La Jolla, California

  • Research Site

    La Mesa, California

  • Research Site

    Languna Niguel, California

Showing 40 of 856 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.